63 / 88
63
Thursday, 22 June 2017
/ Scientific Programme
WFSBP 2017
THU
aa
Thursday, 22 June 2017
T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)
S-56
SYMPOSIUM
08:30–10:00
Auditorium 15
Clinical effects and neural mechanisms of
electroconvulsive therapy in major depression and
schizophrenia
Chair:
Robert Christian Wolf, Germany
Co-Chair: Philipp Thomann, Germany
001
ECT in major depression and schizophrenia:
Indications and clinical effects
Dusan Hirjak, Germany
002
Effects of ECT on brain structure and function:
Lessons from major depressive disorder
Robert Christian Wolf, Germany
003
ECT-related effects on regional brain volume and
structural networks in patients with schizophrenia and
major depressive disorder
Philipp Thomann, Germany
004
Modulation of intrinsic network connectivity by
ECT in patients with schizophrenia and major depres-
sive disorder
Fabio Sambataro, Italy
T6: BIPOLAR DISORDERS: BASIC/ CLINICAL
S-57
SYMPOSIUM
08:30–10:00
Congress Hall A 3
Causes and consequences of inflammation in Bipolar
Disorder (BP)
Chair:
Lars Kessing, Denmark
Co-Chair: Flavio Kapczinski, Brazil
001
Peripheral inflammation in Bipolar Disorder (BP):
Trait and state related alterations
Klaus Munkholm, Denmark
002
Targeting mitochondrial inflammation in Bipolar
Disorder (BP)
Ana Andreazza, Canada
003
Relationships between inflammation, elevated
body mass index, and depressive relapse in Bipolar
Disorder (BP)
David Bond, USA
004
Genetic and central nervous system aspects of
immune dysregulation in Bipolar Disorder (BP)
Bartholomeus Haarman, The Netherlands
T51: MISCELLANEOUS
S-58
SYMPOSIUM
08:30–10:00
Auditorium 12
Novel therapeutics for neurodegenerative disorders
Chair:
Ramón Cacabelos, Spain
001
ASS234, as a new multi-target directed propargyl-
amine for Alzheimer's Disease (AD) therapy
José Marco-Contelles, Spain
002
EB101 immunotherapy against amyloid: A promis-
ing strategy for treating Alzheimer's Disease (AD)
Iván Carrera, Spain
003
The Intelligent Pharmacogenetic Card (PGx-iCard)
for neuropsychiatric disorders
Juan C. Carril, Spain
004
Neuroprotective effects of Atremorine in Cerebral
Ischemia and Parkinson disease-related models
Javier Egea, Spain
005
Basic and clinical studies with E-PodoFavalin-
15999 (Atremorine
®
) in Parkinson's Disease: Selective
dopaminergic neuroprotection and pharmacogenetics
Ramón Cacabelos, Spain
T22: MOLECULAR NEUROBIOLOGY
S-59
SYMPOSIUM
08:30–10:00
Auditorium 10
The relevance of Neuregulin1-ErbB4 signaling for
neuropsychiatric pathomechanisms: Converging
insights from mouse genetics, physiology, and
human studies
Chair:
Peter Falkai, Germany
Co-Chair: Moritz Rossner, Germany
001
The relevance of Neuregulin1-ErbB4 signaling
for neuropsychiatric pathomechanisms: Insights from
human studies
Cyndi Shannon Weickert, Australia
002
Neuregulin1-ErbB4 signaling: Integration at the
network level
Beatriz Rico, United Kingdom
003
The relevance of Neuregulin1-ErbB4: Insights from
mouse physiological analyses
Andrés Buonanno, USA
004
Neuregulin1-ErbB4 signaling: Insights from mouse
genetics
Markus Schwab, Germany